Skip To Main Content
Chuntuan Li on Muck Rack

Chuntuan Li

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chuntuan

Contact Chuntuan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Hedgehog/GLI1 regulates EMT and cancer stem cell properties via the GLI1-Bmi1 axis in diffuse large B-cell lymphoma

|
By Huifang Xiao, Chuntuan Li, Jingjing Gao, Wenqian Xu, Pengliang Xin, Xiongpeng Zhu
| Nature Verified
Abstract R-CHOP-treated diffuse large B-cell lymphoma (DLBCL) shows heterogeneous outcomes. High-risk relapsed/refractory (R/R) patients, especially activated B-cell (ABC) and double-/triple-hit subtypes, have poor prognosis, highlighting an urgent need to uncover the underlying aggressive molecular mechanisms. Epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) properties drive its invasion, metastasis, and drug resistance.
Open in Who Shared Issue with article?

Combined targeting of Hedgehog/GLI1 and Wnt/β‐catenin pathways in mantle cell lymphoma

|
By Chuntuan Li, shengquan Liu, Jingjing Gao, Yanjun He
| Wiley Online Library Verified
1 INTRODUCTION The clinical management of Mantle cell lymphoma (MCL) continues to face enduring challenges due to its incurable nature, frequent recurrence, resistance to drugs, and limited survival rates.1 Despite advancements such as novel therapies targeting CD20 and Bruton's tyrosine kinase (BTK) inhibitors, which initially showed significant clinical remission, patients eventually relapse due to chemotherapy resistance, leading to fatal outcomes.2-5 The Hh pathway has been recognized as...
Open in Who Shared Issue with article?

The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells

|
By Yan Zheng, Chuntuan Li, Pengliang Xin, Huifang Xiao, Yuanling Huang
| cancerci.com
Background Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a therapy target of cancer. We aimed to confirm the effect of dual PI3K/mTOR inhibitor NVP-BEZ235 on cell proliferation and apoptosis in Burkitt lymphoma (BL) cells. Methods Two human BL cell lines, CA46 and RAJI were used in this study. The proliferation of BL cells was detected by manganese tricarbonyl transfer (MTT) assay. Cell cycle and apoptosis assay were examined by flow cytometric analysis.
Open in Who Shared Issue with article?
See all 3 articles